A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)

NCT00945321 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Chemotherapy-Induced Nausea and Vomiting

Interventions

DRUG: aprepitant 165 mg
DRUG: Comparator: aprepitant 185 mg
DRUG: Comparator: fosaprepitant 150 mg
DRUG: Comparator: aprepitant with food

Sponsor

Merck Sharp & Dohme LLC